Page 55 - Read Online
P. 55

Page 16 of 19          Kalloo et al. Metab Target Organ Damage 2023;3:7  https://dx.doi.org/10.20517/mtod.2022.26

               Financial support and sponsorship
               Not applicable.


               Conflicts of interest
               Kalloo J and Priscilla S - no conflicts. Puttanna A works 4 days a week as a national advisor for Sanofi UK.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2023.


               REFERENCES
               1.       North EJ, Newman JD. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like
                   peptide-1 receptor agonists. Curr Opin Cardiol 2019;34:687-92.  DOI  PubMed  PMC
               2.       Buse JB, Wexler DJ, Tsapas A, et al. Erratum. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus
                   report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care
                   2020;43:1670.  DOI  PubMed  PMC
               3.       Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. a consensus report by the American
                   Diabetes Association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 2022;65:1925-66.  DOI
                   PubMed  PMC
               4.       Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1
                   (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ
                   2021;372:m4573.  DOI  PubMed  PMC
               5.       NICE guideline NG28, Type 2 diabetes in adults: management Available from: https://www.nice.org.uk/guidance/ng28 [Last accessed
                   on 6 May 2023].
               6.       UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in
                   overweight patients with type 2 diabetes (UKPDS 34). Lancet; 1998 ;352:854-65.  DOI
               7.       Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale
                   for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10:289-301.  DOI
               8.       Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother 2018;52:86-90.  DOI
                   PubMed
               9.       Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and
                   steroid (glucocorticoid) therapy: a guideline from the joint British diabetes societies (JBDS) for inpatient care group. Diabet Med
                   2018;35:1011-7.  DOI  PubMed
               10.      Hattersley AT, Greeley SAW, Polak M, et al. ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of
                   monogenic diabetes in children and adolescents. Pediatr Diabetes 2018;19 Suppl 27:47-63.  DOI
               11.      Angwin C, Jenkinson C, Jones A, et al; MASTERMIND consortium. TriMaster: randomised double-blind crossover study of a DPP4
                   inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have
                   suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. BMJ Open
                   2020;10:e042784.  DOI  PubMed  PMC
               12.      Available from: https://www.easd.org/virtualmeeting/home.html#!resources/b-results-of-the-trimaster-trial-b [Last accessed on 24 May
                   2023].
               13.      Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients
                   with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised
                   controlled trial. Lancet 2005;366:1279-89.  DOI
               14.      Young LH, Viscoli CM, Schwartz GG, et al; IRIS Investigators. Heart failure after ischemic stroke or transient ischemic attack in
                   insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation 2018;138:1210-20.  DOI  PubMed  PMC
               15.      Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol
                   2021;12:615409.  DOI  PubMed  PMC
               16.      Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol
                   2022;10:284-96.  DOI
               17.  Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early
   50   51   52   53   54   55   56   57   58   59   60